Xarelto is owned by Janssen Pharms.

Xarelto contains Rivaroxaban.

Xarelto has a total of 10 drug patents out of which 2 drug patents have expired.

Expired drug patents of Xarelto are:

• US7592339
• US7585860

Xarelto was authorised for market use on 11 October, 2018.

Xarelto is available in for suspension;oral, tablet;oral dosage forms.

Xarelto can be used as reduction in the risk of recurrence of deep vein thrombosis (dvt) and/or pulmonary embolism (pe) in patients at continued risk for recurrent dvt and/or after completion of initial treatment lasting at least 6 months, reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily, treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment, reduction of risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of vascular etiology) in patients with pad, treatment of deep vein thrombosis (dvt).

Drug patent challenges can be filed against Xarelto from 24 February, 2024.

The generics of Xarelto are possible to be released after 31 July, 2039.